Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer

Journal of the National Cancer Institute

Volumn 94, Issue 21, 2002, Pages 1604-1613

  Smith, Jennifer S ^a   Herrero, Rolando ^b   Bosetti, Cristina ^b   Muñoz, Nubia ^b   Bosch, F Xavier ^b   Eluf Neto, Jose ^b   Castellsagué, Xavier ^b   Meijer, Chris J L M ^b   Van den Brule, Adriaan J C ^b   Franceschi, Silvia ^b   Ashley, Rhoda ^b  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS ANTIBODY; VIRUS DNA;

ADENOCARCINOMA; ADENOSQUAMOUS CARCINOMA; ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; BLOOD ANALYSIS; CANCER RISK; CASE CONTROL STUDY; CHLAMYDIA TRACHOMATIS; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; INVASIVE CARCINOMA; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEXUAL BEHAVIOR; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; WART VIRUS; WESTERN BLOTTING;

EID: 0037032499     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/94.21.1604     Document Type: Article

References (50)

1. International Agency for Research on Cancer (IARC) Working Group on the Evaluation of Carcinogenic Risks to Humans. Human papillomaviruses. IARC monographs on the evaluation of carcinogenic risks to humans. Vol. 64. Lyon (France): IARC; 1995.
2. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9.
3. Moreno V, Bosch FX, Muñoz N, Meijer CJ, Shah KV, Walboomers JM, et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet 2002;359:1085-92.
4. Rawls WE, Tompkins WA, Figueroa ME, Melnick JL. Herpesvirus type 2: association with carcinoma of the cervix. Science 1968;161:1255-6.
5. Muñoz N, de-Thé G, Aristizabal N, Yee C, Rabson A, Pearson G. Antibodies to herpesviruses in patients with cervical cancer and controls. In: de-The G, Epstein MA, zur Hausen H, editors. Oncogenesis and herpesviruses II. IARC Sci Publ No. 11. Lyon (France): IARC; 1975. p. 45-51.
6. Macnab JC. Transformation of rat embryo cells by temperature-sensitive mutants of herpes simplex virus. J Gen Virol 1974;24:143-53.
7. zur Hausen H. Human genital cancer: synergism between two virus infections or synergism between a virus infection and initiating events? Lancet 1982;2:1370-2.
8. Park M, Kitchener HC, Macnab JC. Detection of herpes simplex virus type-2 DNA restriction fragments in human cervical carcinoma tissue. EMBO J 1983;2:1029-34.
9. Galloway DA, McDougall JK. The oncogenic potential of herpes simplex viruses: evidence for a 'hit-and-run' mechanism. Nature 1983;302:21-4.
10. Jones C. Cervical cancer: is herpes simplex virus type II a cofactor? Clin Microbiol Rev 1995;8:549-56.
11. DiPaolo JA. The role of Herpes Simplex 2 in the development of HPV-positive cervical carcinoma. Papillomavirus Rep 1999;10:1-7.
12. DiPaolo JA, Woodworth CD, Coutlee F, Zimonic DB, Bryant J, Kessous A. Relationship of stable integration of herpes simplex virus-2 Bg/II N subfragment Xho2 to malignant transformation of human papillomavirus-immortalized cervical keratinocytes. Int J Cancer 1998;76:865-71.
13. de Sanjose S, Munoz N, Bosch FX, Reimann K, Pedersen NS, Orfila J, et al. Sexually transmitted agents and cervical neoplasia in Colombia and Spain. Int J Cancer 1994;56:358-63.
14. Munoz N, Kato I, Bosch FX, de Sanjose S, Sundquist VA, Izarzugaza I, et al. Cervical cancer and herpes simplex virus type 2: case-control studies in Spain and Colombia, with special reference to immunoglobulin-G subclasses. Int J Cancer 1995;60:438-42.
15. Peng HQ, Liu SL, Mann V, Rohan T, Rawls W. Human papillomavirus types 16 and 33, herpes simplex virus type 2 and other risk factors for cervical cancer in Sichuan Province, China. Int J Cancer 1991;47:711-6.
16. Ferrera A, Baay MF, Herbrink P, Figueroa M, Velema JP, Melchers WJ. A sero-epidemiological study of the relationship between sexually transmitted agents and cervical cancer in Honduras. Int J Cancer 1997;73:781-5.
17. Thomas DB, Qin Q, Kuypers J, Kiviat N, Ashley RL, Koetsawang A, et al. Human papillomaviruses and cervical cancer in Bangkok. II. Risk factors for in situ and invasive squamous cell cervical carcinomas. Am J Epidemiol 2001;153:732-9.
18. Ashley RL, Cent A, Maggs V, Nahmias A, Corey L. Inability of enzyme immunoassays to discriminate between infections with herpes simplex virus types 1 and 2. Ann Intern Med 1991;115:520-6.
19. Munoz N, Bosch FX, de Sanjose S, Tafur L, Izarzugaza I, Gili M, et al. The causal link between human papillomavirus and invasive cervical cancer: a population-based case-control study in Colombia and Spain. Int J Cancer 1992;52:743-9.
20. Eluf-Neto J, Booth M, Munoz N, Bosch FX, Meijer CJ, Walboomers JM. Human papillomavirus and invasive cervical cancer in Brazil. Br J Cancer 1994;69:114-9.
21. Chichareon S, Herrero R, Munoz N, Bosch FX, Jacobs MV, Deacon J, et al. Risk factors for cervical cancer in Thailand: a case-control study. J Natl Cancer Inst 1998;90:50-7.
22. Ngelangel C, Munoz N, Bosch FX, Limson GM, Festin MR, Deacon J, et al. Causes of cervical cancer in the Philippines: a case-control study. J Natl Cancer Inst 1998;90:43-9.
23. Chaouki N, Bosch FX, Munoz N, Meijer CJ, El Gueddari B, El Ghazi A, et al. The viral origin of cervical cancer in Rabat, Morocco. Int J Cancer 1998;75:546-54.
24. Santos C, Munoz N, Klug SJ, Almonte M, Guerrero I, Alvarez M, et al. HPV types and cofactors causing cervical cancer in Peru. Br J Cancer 2001;85:966-71.
25. Evander M, Edlund K, Gustafsson A, Jonsson M, Karlsson R, Rylander E, et al. Human papillomavirus infection is transient in young women: a population-based cohort study. J Infect Dis 1995;171:1026-30.
26. Burk RD, Ho GY, Beardsley L, Lempa M, Peters M, Bierman R. Sexual behavior and partner characteristics are the predominant risk factors for genital human papillomavirus infection in young women. J Infect Dis 1996; 174:679-89.
27. Jacobs MV, Roda Husman AM, van den Brule AJ, Snijders PJ, Meijer CJ, Walboomers JM. Group-specific differentiation between high- and low-risk human papillomavirus genotypes by general primer-mediated PCR and two cocktails of oligonucleotide probes. J Clin Microbiol 1995;33:901-5.
28. Ashley RL, Militoni J, Lee F, Nahmias A, Corey L. Comparison of Western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera. J Clin Microbiol 1988;26:662-7.
29. Ashley RL. Type-specific antibodies to HSV-1 and -2: review of methodology. Herpes 1998;5:33-8.
30. Smith JS, Herrero R, Munoz N, Eluf-Neto J, Ngelangel C, Bosch FX, et al. Prevalence and risk factors for herpes simplex virus type 2 infection among middle-age women in Brazil and the Philippines. Sex Transm Dis 2001; 28:187-94.
31. Wang SP, Grayston JT. Micro immunofluorescence antibody responses in Chlamydia trachomatis infection: a review. In: Mardh PA, Holmes KK, Oriel JD, editors. Chlamydial infections. Amsterdam (The Netherlands): Elsevier-Biomedical Press; 1982. p. 301-16.
32. Breslow NE, Day NE. Statistical methods in cancer research. Volume I - The analysis of case-control studies. IARC Sci Publ 1980;(32):5-338.
33. Karlsson R, Jonsson M, Edlund K, Evander M, Gustavsson A, Boden E, et al. Lifetime number of partners as the only independent risk factor for human papillomavirus infection: a population-based study. Sex Transm Dis 1995;22:119-27.
34. Brinton LA. Epidemiology of cervical cancer-overview. IARC Sci Publ 1992;(119):3-23.
35. Jha PK, Beral V, Peto J, Hack S, Hermon C, Deacon J, et al. Antibodies to human papillomavirus and to other genital infectious agents and invasive cervical cancer risk. Lancet 1993;341:1116-8.
36. Dillner J, Lenner P, Lehtinen M, Eklund C, Heino P, Wiklund F, et al. A population-based seroepidemiological study of cervical cancer. Cancer Res 1994;54:134-41.
37. Daling JR, Madeleine MM, McKnight B, Carter JJ, Wipf GC, Ashley RL, et al. The relationship of human papillomavirus-related cervical tumors to cigarette smoking, oral contraceptive use, and prior herpes simplex virus type 2 infection. Cancer Epidemiol Biomarkers Prev 1996;5:541-8.
38. Dillner J. Antibody responses to defined HPV epitopes in cervical neoplasia. Papillomavirus Rep 1994;5:35-41.
39. Hildesheim A, Mann V, Brinton LA, Szklo M, Reeves WC, Rawls WE. Herpes simplex virus type 2: a possible interaction with human papillomavirus types 16/18 in the development of invasive cervical cancer. Int J Cancer 1991;49:335-40.
40. Lehtinen M, Dillner J, Knekt P, Luostarinen T, Aromaa A, Kirnbauer R, et al. Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: nested case-control study. BMJ 1996;312:537-9.
41. Cowan FM, Johnson AM, Ashley RL, Corey L, Mindel A. Antibody to herpes simplex virus type 2 as serological marker of sexual lifestyle in populations. BMJ 1994;309:1325-9.
42. Graham S, Rawls W, Swanson M, McCurtis J. Sex partners and herpes simplex virus type 2 in the epidemiology of cancer of the cervix. Am J Epidemiol 1982;115:729-35.
43. Corey L, Wald A. Genital herpes. In: Holmes KK, Sparling PF, Mardh PA, Lemon SM, Stamm WE, Piot P, et al., editors. Sexually transmitted diseases. 3rd ed. New York (NY): McGraw-Hill; 1998. p. 285-312.
44. York IA, Roop C, Andrews DW, Riddell SR, Graham FL, Johnson DC. A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes. Cell 1994;77:525-35.
45. Paludan SR, Malmgaard L, Ellermann-Eriksen S, Bosca L, Mogensen SC. Interferon (IFN)-gamma and Herpes simplex virus/tumor necrosis factor-alpha synergistically induce nitric oxide synthase 2 in macropbages through cooperative action of nuclear factor-kappa B and IFN regulatory factor-1. Eur Cytokine Netw 2001;12:297-308.
46. Hara Y, Kimoto T, Okuno Y, Minekawa Y. Effect of herpes simplex virus on the DNA of human papillomavirus 18. J Med Virol 1997;53:4-12.
47. Vonka V, Kanka J, Roth Z. Herpes simplex type 2 virus and cervical neoplasia. Adv Cancer Res 1987;48:149-91.
48. Hildesheim A, Gravitt P, Schiffman MH, Kurman RJ, Barnes W, Jones S, et al. Determinants of genital human papillomavirus infection in low-income women in Washington, D.C. Sex Transm Dis 1993;20:279-85.
49. Remmink AJ, Walboomers JM, Helmerhorst TJ, Voorhorst FJ, Rozendaal L, Risse EK, et al. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. Int J Cancer 1995;61:306-11.
50. Franco EL, Villa LL, Sobrinho JP, Prado JM, Rousseau MC, Desy M, et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 1999;180:1415-23.